ETHICS AND CONFLICTS-OF-INTEREST
|11.1. ||Principles. Members of EHDN should |
the highest personal and professional standards in conducting non-clinical and clinical projects. Real and perceived
conflicts-of-interest should be avoided,
- fully disclose their
research support and any significant financial interest with
manufacturer(s) of commercial products related to the topic of any
presentation for education events in which they participate, and insist
on full and meaningful disclosure of financial support for educational
events to which they are invited to participate.
- not in any
way or manner benefit financially from the information obtained as a
result of their participation or knowledge of EHDN non-clinical or clinical projects. In particular:
- not own or trade in the
equity of a company whose drugs or products are being investigated by
EHDN (an “involved company”) or inform or influence relatives, friends
or others in financial transactions regarding an involved company.
serve as paid consultants to an involved company in relation to the
study drug or related drugs or products of an involved company during
the period of the clinical project, except as requested by the involved
company as an activity or consultation under the auspices of EHDN.
|11.2. ||Education; Confidential Information.
EHDN members have an obligation to act in the public interest and
should be willing to educate the scientific and lay communities so long
as doing so does not disclose confidential information or jeopardize
the successful outcome of any non-clinical or clinical project which is in progress. |
|11.3. ||Policies and Procedures. The Executive Committee may adopt policies and procedures to give effect
to these ethical and conflict-of-interest principles, including the timing of
the application of these principles to clinical projects, permitted activities
and the annual disclosure of certain relationships.|| || |